…a "win" is essentially a scorched earth. Patent that is invalid means anyone that wants to produce and sell can do a generic…Wouldn’t the limited availability of Vascepa API substantially impede competition, at least in the short run? Something close to pure competition results and we know what that does to profits…Again, due to the limited availability of API, wouldn’t it take an extended time for a free-for-all market to ensue?